Biotechnologies
ACCELERATING INNOVATIVE

We Acquire, Develop and Finance Undervalued Biomedical Assets

Slider

Our vision is to create a pipeline of innovative biomedical assets in various stages of development in multiple therapeutic areas. Our strategy will minimize risk, share success and accelerate our technologies from incubation to monetization.

Q BioMed Takes the Stage in the Expanded Access Debate at European Early and Managed Access Program Conference

Q BioMed Orphan Drug VP, who started the first Expanded Access Program Database asked to Speak on Panels and run Roundtable at the Early and Managed Access Program Conference in the UK from October 22nd to 24th 2018 NEW YORK, October 26, 2018 /PRNewswire/ -- Q BioMed...

Q BioMed Provides Important Update on QBM001 Developmental Drug Targeting a Non-Verbal and Minimally Verbal Patient Subset on the Autism Spectrum

Company Further Develops Its Autistic Spectrum Disorder (ASD) Drug Technology and Expects Several Development Partnerships In Anticipation of Clinical Program in 2019NEW YORK, October 9, 2018 /PRNewswire/ --Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration...

Q Biomed Inc. Announces Entry Into Definitive Funding Agreement for $4,000,000

Financing Provides Necessary Capital to Reach Important MilestonesNEW YORK, September 24, 2018 /PRNewswire/ --Q BioMed Inc. (OTCQB: QBIO), is pleased to announce that it has entered into a definitive agreement with Yorkville Advisors Global ('Yorkville') for...

OUR GROWING PIPELINE MITIGATES RISK

Progress
0%

Topical eyedrops for glaucoma

PRECLINICAL

Image is not available
Progress
0%

PRECLINICAL

Chemotherapeutic for liver cancer

Image is not available
Progress
0%

Rare pediatric non-verbal Autism Spectrum Disorder

PRE IND 2/3

Image is not available
Progress
0%

COMMERCIALIZATION

Radio-pharmaceutical for metastatic cancer bone pain

Image is not available
Arrow
Arrow
Slider

OUR PORTFOLIO

METASTATIC CANCER BONE PAIN
CHEMOTHERAPUTIC FOR LIVER CANCER
RARE PEDIATRIC NON-VERBAL DISORDER
TOPICAL EYEDROPS FOR GLAUCOMA & IOP

THE RIGHT
FIRM

Focuses exclusively in the biotechnology and healthcare sectors, targeting a broad spectrum of biomedical products and healthcare solutions. Q’s expertise is in business & product development and the capital formation required for phased advancement of products.

THE RIGHT
SOLUTION

Our team assists companies by utilizing our strategic partners and network of experts to provide public market access for private company assets.  80% of biomedical start ups lack capital and resources to transition from incubation to development and beyond.

THE RIGHT
STRATEGY

Q expects to maximize risk-adjusted returns by focusing on value-driven assets from early stage to near-revenue businesses where the technical, regulatory, and commercial risks have been mitigated or where major valuation inflections are imminent.

Copyright © 2017 Q BioMed, Inc. All Rights Reserved

 

 

CONTACT

366 Madison Ave, 3rd Floor
New York, NY 10022 USA
P: +1 888 357 2435
E: info@qbiomed.com